BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 11698416)

  • 1. Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase.
    Kueffer LE; Lin DY; Amatya N; Serrenho J; Joseph RE; Courtney AH; Andreotti AH
    Biochemistry; 2024 Jan; 63(1):94-106. PubMed ID: 38091504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library.
    Gustafsson MO; Mohammad DK; Ylösmäki E; Choi H; Shrestha S; Wang Q; Nore BF; Saksela K; Smith CI
    PLoS One; 2017; 12(4):e0174909. PubMed ID: 28369144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states.
    Lin DY; Kueffer LE; Juneja P; Wales TE; Engen JR; Andreotti AH
    Elife; 2024 Jan; 12():. PubMed ID: 38189455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A self-scaffolding model for G protein signaling.
    Wang J; Golebiewska U; Scarlata S
    J Mol Biol; 2009 Mar; 387(1):92-103. PubMed ID: 19361438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for Gβγ-mediated activation of phosphoinositide 3-kinase γ.
    Chen CL; Syahirah R; Ravala SK; Yen YC; Klose T; Deng Q; Tesmer JJG
    Nat Struct Mol Biol; 2024 Apr; ():. PubMed ID: 38565696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function.
    Trory JS; Munkacsi A; Śledź KM; Vautrinot J; Goudswaard LJ; Jackson ML; Heesom KJ; Moore SF; Poole AW; Nabet B; Aggarwal VK; Hers I
    Blood Adv; 2023 May; 7(9):1692-1696. PubMed ID: 36342848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
    Alu A; Lei H; Han X; Wei Y; Wei X
    J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of Vibratory Urticaria-Associated Adhesion-GPCR, EMR2/ADGRE2, Triggers the NLRP3 Inflammasome Activation Signal in Human Monocytes.
    I KY; Tseng WY; Wang WC; Gordon S; Ng KF; Lin HH
    Front Immunol; 2020; 11():602016. PubMed ID: 33488598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of dual mechanisms mediating 5-hydroxytryptamine receptor 1F-induced mitochondrial biogenesis.
    Gibbs WS; Garrett SM; Beeson CC; Schnellmann RG
    Am J Physiol Renal Physiol; 2018 Feb; 314(2):F260-F268. PubMed ID: 29046298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
    Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
    Turetsky A; Kim E; Kohler RH; Miller MA; Weissleder R
    Sci Rep; 2014 Apr; 4():4782. PubMed ID: 24759210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bruton's tyrosine kinase in B cell malignancies.
    Hendriks RW; Yuvaraj S; Kil LP
    Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-dependent autophosphorylation of the insulin receptor is positively regulated by Gi-proteins.
    Kreuzer J; Nürnberg B; Krieger-Brauer HI
    Biochem J; 2004 Jun; 380(Pt 3):831-6. PubMed ID: 15025562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.
    Lowry WE; Huang XY
    J Biol Chem; 2002 Jan; 277(2):1488-92. PubMed ID: 11698416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.
    Várnai P; Rother KI; Balla T
    J Biol Chem; 1999 Apr; 274(16):10983-9. PubMed ID: 10196179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase.
    Lowry WE; Huang J; Lei M; Rawlings D; Huang XY
    J Biol Chem; 2001 Nov; 276(48):45276-81. PubMed ID: 11577078
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.